Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$119.08 USD

119.08
722,614

+0.58 (0.49%)

Updated Sep 4, 2024 02:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's How J&J (JNJ) Will Roll Out Drug Sector Q3 Earnings

by Zacks Equity Research

J&J's (JNJ) Pharma segment is expected to have performed above market while the Medical Devices segment might have been hurt by the COVID-19 impact in the third quarter.

GlycoMimetics' Rivipansel Gets Rare Pediatric Disease Status

by Zacks Equity Research

GlycoMimetics' (GLYC) rivipansel gets a Rare Pediatric Disease designation by the FDA for the treatment of SCD in patients 18 years old and younger.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approves New Uses of PFE, JNJ & GSK's Drugs

by Kinjel Shah

New indications of Glaxo's (GSK) Nucala J&J's (JNJ) Simponi Aria and Pfizer's (PFE) Xeljanz get FDA's nod.

Alnylam Releases Positive Top-Line Rare Disease Lumasiran Data

by Zacks Equity Research

Alnylam (ALNY) releases positive top-line data from the ILLUMINATE-B pediatric phase III study of lumasiran, in development for the treatment of PH1.

Blueprint Medicines Rises YTD on Robust Ayvakit Progress

by Zacks Equity Research

Blueprint Medicines' (BPMC) lead drug Ayvakyt/Ayvakit approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's efforts to expand the drug's label are promising as well.

AbbVie Elezanumab Gets FDA's Fast Track and Orphan Drug Tags

by Zacks Equity Research

AbbVie's (ABBV) elezanumab is presently being evaluated in a phase II study for spinal cord injury.

AC Immune's Candidate Fails in Alzheimer's Disease Study

by Zacks Equity Research

The failure of AC Immune's (ACIU) study on Alzheimer's disease brings this challenging but promising space in focus.

Pfizer Seeks Xalkori's Label Expansion, Gets Priority Review

by Zacks Equity Research

Pfizer's (PFE) sNDA seeking label expansion of lung cancer drug, Xalkori, for a hematologic indication gets priority review from the FDA.

Novartis Announces Data on Tafinlar, Mekinist & Piqray at ESMO

by Zacks Equity Research

Novartis (NVS) announces data from late-stage studies on Tafinlar, Mekinist and Piqray at ESMO 2020.

Rigel Announces Sponsored Mid-Stage Coronavirus Therapy Study

by Zacks Equity Research

Rigel Pharmaceuticals (RIGL) is developing its thrombocytopenia drug, Tavalisse, as a potential treatment for hospitalized COVID-19 patients.

The Zacks Analyst Blog Highlights: Novartis, Zoom Video, Caterpillar, Microsoft, Cisco, Clorox and LHC Group

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novartis, Zoom Video, Caterpillar, Microsoft, Cisco, Clorox and LHC Group

Corcept's Lead Drug Korlym Aids Growth, Heavy Reliance a Woe

by Zacks Equity Research

Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.

Sheraz Mian headshot

Top Stock Reports for Novartis, Zoom Video & Caterpillar

by Sheraz Mian

Today's Research Daily features new research reports on 12 major stocks, including Novartis (NVS), Zoom Video Communications (ZM) and Caterpillar (CAT).

Novartis' Eye Drug's Safety Label Update Approved by EMA

by Zacks Equity Research

Novartis' (NVS) eye drug Beovu's safety label update receives approval from the Committee for Medicinal Products for Human Use.

Novartis Reports Positive Data on Beovu for DME Indication

by Zacks Equity Research

Novartis (NVS) announces positive data on Beovu from an ongoing late-stage study for the DME indication.

AstraZeneca's Fasenra Meets Endpoint in Rhinosinusitis Study

by Zacks Equity Research

AstraZeneca (AZN) is developing Fasenra under a clinical program as a potential treatment for chronic rhinosinusitis with nasal polyps.

Roche Expands Multiple Sclerosis Portfolio, Starts Studies

by Zacks Equity Research

Roche (RHHBY) expands its MS portfolio by adding pipeline candidate, fenebrutinib. The company also initiates MS studies on fenebrutinib and Ocrevus.

Novartis (NVS) Releases Positive Data on Enerzair Breezhaler

by Zacks Equity Research

Novartis (NVS) posts favorable data on asthma treatment Enerzair Breezhaler at the ERS International Congress 2020.

Ionis to Acquire Remaining Stake in Akcea, Stocks Rally

by Zacks Equity Research

Ionis (IONS) is set to acquire the remaining 24% stake in Akcea Therapeutics (AKCA) in an all-cash deal.

The Zacks Analyst Blog Highlights: Verizon Communications, Novartis, Abbott Laboratories, AT&T, Intuitive Surgical and Northrop Grumman

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Verizon Communications, Novartis, Abbott Laboratories, AT&T, Intuitive Surgical and Northrop Grumman

Bayer Submits Application for Heart Failure Drug in China

by Zacks Equity Research

Bayer (BAYRY) submits a regulatory application seeking approval for vericiguat to treat patients with symptomatic chronic heart failure in China.

Novartis Announces Positive Data on PNH & Cholesterol Drugs

by Zacks Equity Research

Novartis (NVS) announces new positive data on its PNH drug, LNP023, and an investigational cholesterol-lowering treatment, inclisiran.

Kinjel Shah headshot

Pharma Stock Roundup: AZN's Coronavirus Antibody Combo Study, & Other Updates

by Kinjel Shah

AstraZeneca (AZN) begins dosing in phase I study on antibody cocktail therapy to treat COVID-19. Glaxo's (GSK) Blenrep gets approval in Europe.

Sheraz Mian headshot

Top Stock Reports for Verizon, Novartis & Abbott

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications (VZ), Novartis (NVS) and Abbott Laboratories (ABT).

PTC Therapeutics Gets First Milestone Payment for SMA Drug

by Zacks Equity Research

PTC Therapeutics (PTCT) gets first commercial milestone payment from Roche for first commercial sale of Evrysdi in the United States.